Travel Vaccines Increase Revenues 52%

With international travel steadily increasing post-pandemic, so have the sales of travel vaccines. 

For example, Denmark's Bavarian Nordic A/S announced today its interim financial results and business progress for the first three months of 2025, which includes travel health revenue increasing by 52% to DKK 680 million compared to the first quarter of 2024.

As of May 9, 2025, the increase is primarily driven by increased demand for rabies and tick-borne encephalitis vaccines.

Furthermore, Bavarian Nordic confirmed positive insights for its mpox and chikungunya vaccines.

Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic, said in a press release, "We had a very strong first quarter for our Travel Health business, demonstrating 52% growth year over year."

"We also recorded our first U.S. sales of the chikungunya vaccine after its approval in February 2025. Our phased launch plan for the vaccine is progressing as planned, with the first European markets coming online over the next couple of months. We are also continuing our efforts to expand the regulatory approvals to other territories."

"Chikungunya represents an increasing public health threat across the globe, and we are proud to have entered our first partnership to improve access to the vaccine for low- and middle-income countries."

Regarding public preparedness, the freeze-dried version of the JYNNEOS® (MVA-BN®, IMVAMUNE®) vaccine was approved by the U.S. Food and Drug Administration (FDA) in March to prevent smallpox and mpox disease in adults.

As of May 2025, clades 1 and 2 of mpox remain global health risks, especially in Africa.

The approval supports the ongoing contract with the U.S. government to stockpile the vaccine. In May, the U.S. government exercised additional options valued at $143.6 million under the existing agreement to supply a freeze-dried formulation of JYNNEOS smallpox vaccine, with planned delivery in 2026.

Overall, the Company's revenue for the first three months increased 62% to DKK 1,347 million.